Prednisone and T-Cell Subpopulations

Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment

“…Anti-inflammatory effects are postulated but it remains unclear to what extent inflammation contributes to this disease. Similarly, while it is demonstrated that moderate doses of corticosteroids result in profound decreases in circulating peripheral blood lymphocytes, 54 as well as thoracic duct lymphocyte number and overall thoracic duct flow, 55 it is unclear if the magnitude and duration of these effects are sufficient to affect clinical response in protein-losing enteropathy. Unfortunately, as with heparin therapy, the side effects of corticosteroid use can be prohibitive.…”

Progression of varicella-zoster virus necrotizing retinopathy in an HIV-negative patient with transient immune deviation

“…The parenteral acyclovir therapy was administered as recommended for the treatment of ARN, and oral maintenance therapy with valaciclovir (for better bioavailability and less frequent daily administration) was continued for 3 months to decrease the risk of contralateral involvement [2,9]. Although immunosuppression with oral prednisolone 1 mg/kg daily for 1 week may alter the natural course of disease by suppressing the inflammatory response, it is unlikely to cause the depressed CD4 and CD4/CD8 ratio [11]. The transient decrease of the CD4 and CD4/CD8 lymphocyte ratio, which may be induced by the VZV infection [1,7,10], probably contributed to the lack of prominent inflammatory response.…”

Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model

“…The proliferation of activated T 1 cells is enhanced by I 2 [ 52 , 53 ]. Both processes of activation and proliferation are inhibited by the complex B7/CTLA-4 ( Q ), by a factor 1/(1 + Q / K TQ ), and prednisone ( S ) depletes T 1 cells [ 8 ]. Hence, T 1 satisfies the following equation: Similarly, note that T r also controls the activation of T 8 cells [ 57 ].…”

“…Steroids, or cortocosteroids, are anti-inflammatory drugs, frequently used in non-small cell lung cancer (NSCLC) and melanoma patients treated with ICI [5,6]; they reduce toxicity, but also impair immunotherapy [7]. Steroids commonly used include prednisone and dexamethasone, that are known to decrease the number of cytotoxic lymphocytes [8,9], hence also the concentration of inflammatory cytokines, such as IL-1, IL-6 and TNF-α [10]. Some studies show that using steroid too early after infusion of ICI decreases progression free survival (PFS) and overall survival (OS) [5,[11][12][13], but a recent review on metastatic analysis suggests that steroids, that are used only to mitigate adverse events of ICI, do not negatively affect overall survival [14].…”